Circulating tumor cells in breast cancer: applications in personalized medicine

被引：0
作者：
Jin Sun Lee
Mark Jesus M. Magbanua
John W. Park
机构：
[1] University of California San Francisco,Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center
来源：
Breast Cancer Research and Treatment | 2016年 / 160卷
关键词：
Breast cancer; Circulating tumor cells (CTCs); Personalized medicine; HER2; Estrogen receptor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Recent technological advancements in rare cell analysis have facilitated the detection of circulating tumor cells (CTCs) in the blood of patients diagnosed with breast and other types of cancers. Numerous clinical studies involving the enumeration of CTCs in breast cancer patients have unequivocally demonstrated the prognostic value of these cells. Evidence from recent molecular studies indicates that CTCs may be potential surrogate markers for systemic disease. As such, real-time assessment of therapeutic biomarkers in breast CTCs, such as the estrogen receptor (ER) and the human epidermal growth factor receptor 2 (HER2), may have a tremendous impact in guiding-targeted cancer therapy. In this review, we discuss the clinical implications of CTC detection and its potential utility for personalized medicine in breast cancer.
引用
收藏
页码：411 / 424
页数：13
相关论文
共 1299 条
  • [1] Witzel I(2015)Targeted therapies in breast cancer: new approaches and old challenges Breast Care (Basel) 10 157-158
  • [2] Muller V(2014)Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells? Breast Care (Basel) 9 16-21
  • [3] Alunni-Fabbroni M(1991)Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases J Clin Oncol 9 1749-1756
  • [4] Muller V(1992)Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis J Clin Oncol 10 1534-1539
  • [5] Fehm T(2000)Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer N Engl J Med 342 525-533
  • [6] Janni W(2004)Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases Clin Cancer Res 10 6897-6904
  • [7] Rack B(2008)Detection, clinical relevance and specific biological properties of disseminating tumour cells Nat Rev Cancer 8 329-340
  • [8] Cote RJ(2002)Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance J Clin Oncol 20 3404-3412
  • [9] Rosen PP(2004)Circulating tumor cells, disease progression, and survival in metastatic breast cancer N Engl J Med 351 781-791
  • [10] Lesser ML(2005)Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer J Clin Oncol 23 1420-1430
12345678910